Category Archives: Nano medicine

A cheap, safe, self-charging battery that delivers high power for decades without ever needing a charge? That's a game changer. California-based company NDB is making some outrageous promises with its nano-diamond battery technology, which could completely disrupt the energy generation, distribution and provision models if deployed at scale.

Each of these batteries, which can be built to fit any existing standard or shape, uses a small amount of recycled nuclear waste, reformed into a radioactive diamond structure and coated in non-radioactive lab diamonds for safety.

We explained the technology in detail in our original NDB nano-diamond battery breakdown, but we also had the opportunity to speak with members of the NDB executive team. CEO Dr. Nima Golsharifi, COO Dr. Mohammed Irfan and Chief Strategy Officer Neel Naicker joined us on a Zoom call to talk about the technology and its potential for disruptive change.

What follows is an edited transcript.

Dr Nima Golsharifi: Our battery is based on the beta decay and alpha decay of radioisotopes. The technology we have encapsulates this radioisotope in a very safe manner, which allows it to be used in basically any application that current batteries are being used for.

Loz: The particular type of carbon that you're using, where do you get that?

Nima: Basically we're using a range of different isotopes, not just one particular one, but access to these are through different methods. We have some partners in collaboration at the moment that can provide us with them.

But they're basically taken from nuclear waste. So we can recycle them and use the raw materials for our application. But we can also synthesize it in large scale in our facility. So both are possibilities.

Loz: OK. So what part of a nuclear reactor creates this waste? What's it doing before it becomes waste?

Nima: Basically, some parts of the nuclear reactor, like the moderator and the refractor, are being exposed to radiation from the fuel rods. Over time they become radioactive themselves. That's the part that they have to store as nuclear waste.

So this part could be taken away, and through some process, either gasification or some other processes we've designed, we can convert that into a useful raw material for our batteries.

Sheikh Mohammed Irfan: Dr. Nima, maybe you can also talk about how big of a waste problem that is for the nuclear industry currently.

Nima: Sure. At the moment, their expenditure is more than a hundred million dollars every year. Nuclear waste is a very large issue across the world. And beside this, there's basically no other way to re-use it in a safe solution.

So what we're doing covers two challenges in one. Converting nuclear waste into a battery that generates power in a very safe manner. Once this battery is used and it can have a very long life span it becomes a very safe byproduct that's of no harm to the environment.

Loz: Right. So I saw a number somewhere that these batteries can last for 28,000 years.

Nima: Let me correct that. It depends on the type of radioisotope you're using, and for every application the lifetime is different. But what we can say is that the battery would operate for the lifetime of the application itself, for sure. For some applications, much higher. So if you're talking about electric vehicles, our battery could run for around 90 years without the requirement of recharging.

When it comes to something like consumer electronics, it'd be more like 9 years. In some small sensor applications, it can go for up to 28,000 years.

NDB

Loz: I understand. So what sort of quantities of this waste are there around the world? Is this super common stuff, or is it reasonably finite?

Nima: Basically we're covering two different kinds of nuclear waste. One is intermediate, and the other is high level. So there will be a time where we have recycled the entire amount of nuclear waste, and we'll need new solutions for the raw material. But as I mentioned, we'll be able to produce this raw material through other methods, including transmutation.

That's a process that's currently being used, and not something we've invented ourselves. It was invented by MIT, and it involves a centrifuge to separate out the isotopes. The main ingredient is nitrogen, which is the major component of air, so it's a very cheap solution.

Loz: So you've got your nuclear waste, it's obviously dangerous for humans. How does it become safe to be used in a battery?

Nima: Basically, we can generate a high amount of cover from the radioactive substance. We're using a combination of technologies within our structure that can make it very safe to users. Mainly it comes down to the fact that we're using diamond structures.

Diamond itself has different interesting properties. It's one of the best heat sinks available at the moment, for example. That on its own covers thermal safety. When it comes to mechanical safety, diamond is one of the strongest materials in the world. 11.5 times stronger than steel. So again, that itself makes the battery tamper-proof and safe.

In addition to that, we have a combination of other technologies, including the implantation of the radioisotopes within the diamond structure, which stops the spread of the radioisotopes even if the structure is broken down which is kind of impossible without access to specific tools like lasers and others.

So in general I can say it's a combination of technologies that we've either innovated or invented that create a very safe structure as a battery.

Irfan: I'd like to add to that, that using radioisotopes as a source for energy is not new. We have nuclear medicine, where patients are treated with controlled equipment, which has always given effective results. Similarly, we have had nuclear-powered submarines and aircraft carriers. Of course, that's a completely different process, but it's been able to successfully and safely deliver power and energy without safety issues.

What Dr. Nima has highlighted is that the choice of diamond as a material is one of the strongest natural materials, and it acts as a powerful shielding and protection mechanism.

Loz: Right. Can you describe how the energy is extracted and harnessed?

Nima: Maybe I can give an example that could help you understand. Let's go to solar cells, everyone's familiar with those. These convert the energy from light radiation into electricity in photovoltaic cells.

In our case, we're converting the radiation from alpha/beta decay alpha and beta radiation directly into electricity. And the mechanism we're using is simple crystalline diamond. As I mentioned before, we have another layer, which is fully crystalline diamond, creating extra shielding and safety for this structure.

Neel Naicker: What Nima's describing is how the radioactivity produced by the body is actually more than what you get from these batteries. They're quite safe.

Loz: So in terms of evaluating batteries for use in cars, eVTOLs and things like that, the main metrics seem to be energy density, power density, safety in a crash, that sort of thing. Do you know what sort of figures you're looking at with these batteries?

Nima: When it comes to energy density, the energy density of a basic radioisotope is far beyond anything else on the market.

When it comes to power density, the solution we have will give a higher level. But compared to the way that energy density is higher, power density is not that much higher. But it's still significantly better than other batteries in the market.

And as far as crashes, no crash could break down our structure at all. Because you're using the diamond, and the specific mechanisms that make it stronger. The only way to get through the structure we have is the use of specific tools and lasers, which are quite expensive.

Neel: Another way to look at this is to think of it in an iPhone. With the same size battery, it would charge your battery from zero to full, five times an hour. Imagine that. Imagine a world where you wouldn't have to charge your battery at all for the day. Now imagine for the week, for the month How about for decades? That's what we're able to do with this technology.

Loz: It would strike at the heart of the disposable model the phone companies tend to use.

Neel: You've hit the nail on the head there. A couple of things. One is the ability for us to power things at scale. We can start at the nanoscale and go up to power satellites, locomotives Imagine that.

Secondly, we're taking something that's a big negative radioactive waste, very dangerous and turning it into something productive that provides electricity.

The third thing is that we wanna use this technology to get low-cost electricity to places that need it. We've now disrupted the whole mechanism of the creation and storage of power. There's a lot of infrastructure needed before you can flip a light switch and a light comes on.

But with what we've created, you don't need that infrastructure. You could put one of these batteries in a home, and boom, you've eliminated the whole infrastructure. Imagine the disruption that's gonna cause, for good or for bad. It'll upset a few people.

We've taken something that's really harmful to the environment, a problem, and created energy. And for places that don't have the electrical infrastructure in place, we want to provide that at a very low cost.

NDB

Loz: Let's talk about cost a little. Obviously lithium batteries cost a lot, they're a primary component of the cost of electric vehicles. Do you guys have a sense for what these things could cost in a commercial environment?

Nima: Yes, we've done financial modelling around this. A lot of applications have been considered. What we can say is it'll depend on the application, but it should be at a good competition level with current lithium-ion batteries.

In some cases, you're a little bit higher in price for production, and in others, when it goes to scale, we're a cheaper solution. Let me give you an example. Take the battery for a Tesla car, it costs somewhere in the region of US$9-10K. Our battery will cost something in the region of US$7-8K. But it's different in different applications.

Loz: So, cheaper and it never needs charging, and it lasts for vastly longer than any lithium cell.

Irfan: Not only is it a few thousand cheaper for the battery pack, but ours recharges itself. So on a Tesla, you need to recharge, stop, over time the battery wears itself out. Ours lasts for a long time.

We'll probably have them available under some sort of subscription model, pay as you go, but it'll be substantially cheaper than what the mechanism is today for a Tesla car.

Loz: Extraordinary. How far along is this technology? How far are we off mass production? Where are you at with prototyping and testing?

Nima: We're in the prototyping stage at the moment. We've completed the proof of concept, and we're about to start the commercial prototype. However, the pandemic has happened, and the lab has been shut down for some time.

But basically once the laboratories are open, we do require around 6-9 months to complete our commercial prototype, and following that to go through the regulatory process, to bring the first few applications for the battery into the market in less than two years' time.

Loz: So it's not far off.

Neel: Just to give you an example, we'll take Google, which has data centers all across the world. Amazon, Facebook, all of these companies. In confidential conversations we've had with some of these parties, we've spoken about how they use and dispose of more Uninterruptible Power Supplies (UPS) than anyone on the planet. Google always has to be on. And those UPS units have a use by date, they have to discard them.

Our product will be able to support that, while reducing the carbon footprint, and lasting far, far longer. That's a game changer when you consider how big an operation something like AWS is. It'll be a huge product for that.

A secondary product will be for the satellite market, where there'll be no regard for whether it's radioactive or not. Low-power satellites, we'll be able to power those for a long, long time without having any regard to whether they're facing the Sun, or getting any Sun on their solar panels, or whatever.

It changes the whole dynamic. Not only have we disrupted the whole energy infrastructure for creating and delivering power, we can also make big changes to the business model for a lot of companies. Big concerns can just become negligible.

This will change a lot of industries. In the future, we could look at using these to power nanorobots moving inside the body. It works from the nanoscale up to large scale. We think it'll be very impressive.

Loz: So the limits on this technology will be what, availability of the raw materials? Regulations? Do you see any regulatory barriers?

Irfan: It's a good question. We've done a comprehensive study on the regulatory and compliance aspects of our technology. Fortunately there are other devices already on the market that use radioisotopes and radioactive material inside them. Some are in the medical industry, like pacemakers. There are already different types of regulations in place.

So the matter here would be our design complying to those regulations, and we've been doing that over time.

Neel: In your home, you'll have smoke detectors, right? All of those have the same radioactivity as well. That's one point.

When it comes to availability, there's enough raw materials out there that we can develop for a long time. That's not the issue. Also, on the regulatory side there are some markets we can go into immediately without any concerns there. Aerospace, military, many others where there aren't the same requirements for compliance.

For a car, it may be different. For a hearing aid, it may be different, or a consumer product. But there are some applications where it won't be a problem at all.

Loz: Right. This is perhaps a bit of a crass question to ask, but do you guys have to pay for this nuclear waste, or are people paying you to take it away?

Irfan: (Laughs) I'm glad you brought that up! We've got a few places that have offered to pay us to take it away. It's a nuisance for them. They have to store it, and you can imagine the regulations around that. In many cases, they have to keep the public a certain distance away. They'll actually pay us to take this stuff away.

So it's a secondary opportunity for us from a revenue standpoint, and we've discussed this with several partners.

Loz: What a wonderful business to be in, where you're paid to take your own raw materials.

Neel. I wanna drive one thing home. If you take a look at the map of energy use in the world, and the map of wealth in the world, they're very similar. One thing we're trying to do with our application is trying to get some of these devices out to places where kids don't have electricity to do their homework, or to power clean water technology.

We're very adamant that this be a component of our business. And while we can't mention too many names, we've spoken with several big partners who would support this effort. Some of these companies feel they need to do good in the world, and providing electricity to places across the world that don't have it is a great opportunity for them.

Again, they don't have the huge infrastructure in place. But we don't need the infrastructure. We don't need power stations, or power lines, or any of that, to provide power. We're adamant as a team that we will give back in a major way that today's infrastructure won't allow.

Loz: In terms of the IP around this, how much do you guys own, and how much competition do you expect?

Irfan: Right now, we have patents pending around our technology. I think we're quite ahead of the competition that exists in the market, we started much earlier than the others and our technology is more advanced.

We thank the NDB team members for their time and look forward to learning more as development progresses.

Source: NDB

See more here:
Interview: The NDB team on its revolutionary nano-diamond batteries - New Atlas

Dublin, Aug. 12, 2020 (GLOBE NEWSWIRE) -- The "Nanotechnology Market - Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Nanotechnology includes fields of science as diverse as molecular nanotechnology, surface science, organic chemistry, molecular biology, semiconductor physics, energy storage, micro-fabrication, and molecular engineering. The technology finds applications in a gamut of industries such as medicine & healthcare, environment, ICT, energy, nano-EHS, and others. A key application of nanotechnology is found in electronics and semiconductor products segment, which is estimated to grow at a substantial CAGR of 15.01% through to 2025.

Nanotechnology Market Growth Drivers:

Nanotechnology Market Trends:

Nanotechnology Market Challenges:The most challenging aspect in the nanotechnology market is scalability of production. Even though nanomaterials impart an outstanding functional performance in the laboratory or prototype stage, the scalability factor is dwarfing the nanotechnology market size. Hence, some of the most propitious applications are in the R&D stage. However, in the future, significant developments are expected in the application of nanotechnology with a profitable commercialization in the automotive, aerospace, and sporting goods industry. Furthermore, the technology will help in effective treatment of cancer which will support the vendors in the nanotechnology market.

Nanotechnology Market Research Scope:The base year of the study is 2020, with forecasts up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the nanotechnology market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The nanotechnology market research report also analyses the application of the same in various industries by product type that includes nano composites, nano devices, nano tools, nano materials, and others.

Key Topics Covered:

1. Nanotechnology Market - Overview2. Nanotechnology Market - Executive summary

3. Nanotechnology Market

4. Nanotechnology Market Forces

5. Nanotechnology Market -Strategic analysis5.1. Value chain analysis5.2. Opportunities analysis5.3. Product life cycle5.4. Suppliers and distributors Market Share

6. Nanotechnology Market - By Type (Market Size -$Million / $Billion)6.1. Market Size and Market Share Analysis 6.2. Application Revenue and Trend Research6.3. Product Segment Analysis

7. Nanotechnology Market - By Applications (Market Size -$Million / $Billion)7.1. Introduction7.2. Medicine and Healthcare Diagnosis7.3. Environment7.4. Energy7.5. Information and Communication Technologies7.6. Nano-EHS

8. Nanotechnology - By End Use Industry(Market Size -$Million / $Billion)8.1. Segment type Size and Market Share Analysis 8.2. Application Revenue and Trends by type of Application8.3. Application Segment Analysis by Type

9. Nanotechnology - By Geography (Market Size -$Million / $Billion)9.1. Nanotechnology Market - North America Segment Research9.2. North America Market Research (Million / $Billion)9.3. Nanotechnology - South America Segment Research9.4. South America Market Research (Market Size -$Million / $Billion)9.5. Nanotechnology - Europe Segment Research9.6. Europe Market Research (Market Size -$Million / $Billion)9.7. Nanotechnology - APAC Segment Research9.8. APAC Market Research (Market Size -$Million / $Billion)

10. Nanotechnology Market - Entropy10.1. New product launches10.2. M&A's, collaborations, JVs and partnerships

11. Nanotechnology Market Company Analysis11.1. Market Share, Company Revenue, Products, M&A, Developments11.2. include Nanosys11.3. QD Vision11.4. Arkema11.5. 10Angstroms11.6. 10x MicroStructures11.7. 10x Technology Inc11.8. 3M 3rd Millennium Inc11.9. 3rdTech Inc

For more information about this report visit https://www.researchandmarkets.com/r/r2psqq

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the article here:
Opportunities in the World Nanotechnology Market to 2025 - Application of Nanotechnology in Wastewater Treatment and Enhanced Renewable Energy Driving...

SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Cellics Therapeutics, Inc.. (Cellics) announced today that results of the study that evaluates the potential benefits of macrophage and pulmonary epithelial nanosponges in neutralizing SARS-CoV-2 infectivity have been published in Nano Letters, entitled Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity, based on research conducted by its founder, Liangfang Zhang, Ph.D.http://pubs.acs.org/doi/abs/10.1021/acs.nanolett.0c02278

As new information about COVID-19 continues to emerge almost on a daily basis, the virus has already demonstrated its ability to mutate and became more infectious, raising doubts about the viability of an effective vaccine and potential future therapies. A therapy that is agnostic to future mutations and has the potential to address future novel viral pandemics is extremely attractive. Treatments that target the affected host cell rather than the infectious agent may offer an opportunity to address future mutations and novel viral outbreaks.

The published study was initiated to evaluate the potential of nanosponges derived from human cells as a therapeutic for the treatment of COVID-19. The study was a collaborative effort between the Department of NanoEngineering at the University of California San Diego Jacobs School of Engineering and the Department of Microbiology and National Emerging Infectious Diseases Laboratories at the Boston University School of Medicine.

Nanosponges derived from macrophages and human pulmonary epithelial cells were tested as it is understood that SARS-CoV-2 enters the cells via known receptors (ACE-2 and CD147) and maybe other unknown receptors. Macrophage and pulmonary epithelial nanosponges were incubated with SARS-CoV-2 infected cells to assess if nanosponges are able to neutralize live SARS-CoV-2 virus. Both macrophage and pulmonary epithelial cell nanosponges demonstrated significant neutralization of SARS-CoV-2 infectivity after two hours of incubation in a concentration dependent manner.

This data represents a validation of the nanosponge platform and our approach of identifying the affected host cell to develop nanosponges as a therapy, said Steve Chen, MD, President and Chief Medical Officer, Cellics Therapeutics. The nanosponge technology allows the therapy to be mutation and virulence factor agnostic, making it a potential universal anti-viral agent for future viral outbreaks. Previous work has shown that macrophage nanosponges neutralized inflammatory cytokines, which are involved in the cytokine storms described in COVID-19 patients. We are particularly excited with the macrophage nanosponges data as a potential therapy to neutralize both the viral activity and the downstream complications associated with COVID-19. We look forward to further validation studies and mapping out a potential path forward to deliver this promising therapy to patients.

Cellics holds exclusive global rights for the development and commercialization of red blood cell and white blood cell nanosponges, including macrophage nanosponges for treatment of various diseases from the University of California, San Diego. Currently, Cellics is developing macrophage nanosponges for the treatment of sepsis.

About Nanosponge Platform Technology

Our proprietary platform technology strips cell membranes of their intracellular contents and allows us to create nanosponges from these membranes to be leveraged as a therapeutic product (Nanosponge Technology). These nanosponges are designed to counteract diverse disease pathologies by acting as biomimetic decoys to sequester and neutralize biological molecules that would otherwise attack host cells. Examples of such harmful agents include toxins, inflammatory cytokines and viruses. The cell membrane forming the outer layer of the nanosponges is selected according to the disease pathology, specifically which host cells are under attack. Nanosponges leverage the natural bioactivity of human cell membrane receptors for therapeutic efficacy. With the advantage of their small size and large quantity, nanosponges outcompete host cells in binding and sequestering biological molecules.

Product development currently emphasizes the use of nanosponges made of human red blood cell membrane and white blood cell membrane for the treatment of bacterial infections and inflammatory diseases. A similar working principle can be applied with membranes of other cell types, making nanosponges suitable for large and diverse disease areas. We have achieved proof of concept in animal models in a range of disease areas.

About Cellics

Cellics Therapeutics, Inc. (Cellics or Company) is a privately held development stage pharmaceutical company founded in 2014 by UC San Diego professor Liangfang Zhang based on his award-winning Nanosponge Technology. Cellics was created with the goal of applying the Nanosponge Technology to treat and prevent diseases.

Cellics is committed to saving lives and improving patients health using innovative biomimetic nanomedicines. The Companys primary focus at this time is on autoimmune and inflammatory diseases and difficult-to-treat infectious diseases. Cellics also aims to develop best-in-class vaccines for various diseases. The Company is currently on schedule to advance its lead product candidate CTI-005 to human clinical trials for the treatment of MRSA pneumonia.

It is the passion and goal of Cellics to use advanced technology to help patients live healthier and longer lives. Visit us at cellics.com.

About UC San Diego Jacobs School of Engineering

The Jacobs School of Engineering at the University of California San Diego offers excellence at scale in research, education, public service, and technology transfer. The Jacobs School ranks first among all public engineering schools for research expenditures per faculty member. These entrepreneurial faculty lead teams that work across disciplines and industries to tackle the toughest challenges that no lab, department or company can handle alone. At the Jacobs School of Engineering, we make bold possible. Visit us athttp://jacobsschool.ucsd.edu/

Forward-looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, any one of which may cause actual results to be materially different from these forward-looking statements. These factors include, without limitation, the ability to duplicate the study results in future studies; the timing and success of our development of CTI-005, CTI-008, CTI-105, CTI-108, and other pipeline candidates; the ability to successfully scale-up our manufacturing process; the timing, costs, conduct, and outcome of our clinical study; and the indication(s) for which our pipelines may be developed. The forward-looking statements in this press release reflect the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contacts

Steve Chen, MDPresident and Chief Medical OfficerCellics Therapeutics, Inc.(858) 412-6148schen@cellics.com

UC San Diego Media ContactIoana PatringenaruPublic Information RepresentativePhone: 858-822-0899ipatrin@ucsd.edu

Source: Cellics Therapeutics, Inc.

Excerpt from:
Cellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters - BioSpace

NEW YORK, June 17, 2020 /PRNewswire/ -- The globalNanocellulose marketis forecast to reach USD 1.08 Billion by 2027, according to a new report by Reports and Data. The market is seeing an expanded interest from the composites sector owing to its critical characteristics, including biodegradability, non-toxicity, and sustainability, along with thixotropic Nanocellulose properties. However, volatile prices of raw materials arising necessity for exploring and adopting other content as a substitute to reduce the overall cost of the operation will be hampering the demand for the market.

Cosmetics would have substantial potential for Nanocellulose across the forecast period. It is used as a synthetic covering agent for fingers, eyes, eyebrows, or eyelashes in cosmetics. The product also provides antioxidant properties and is now used in products for sun care. It is also used for wound dressings in the surgical profession and regenerative medicine. Other uses include pharmaceuticals, tobacco filter additives, computer components, electronic displays, condensers, lithium battery films, lightweight body armor, loudspeaker membranes, and ballistic glass. However, low awareness about product use and high prices may, in the coming years, somehow hamper the demand. Nano fibrillated cellulose held the highest share in the overall market in 2019.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/3207

They possess exceptional properties, including superior strength, lightweight, transparency, and rigidity, among others, which makes them viable for many commercial applications across composites, oil & gas, food & beverage, automotive, aerospace, and personal care industries. Nano-fibrillated cellulose could also be a future replacement for plastic films in composite packaging due to the low oxygen permeability. The composites segment was the largest application segment in the overall market in 2019 by volume. Nowadays, composites are used widely in many applications. It is used in refurbishments as filler stuff. End-users are increasingly concerned about the application of synthetic fillers in composites and the environmental concerns associated with that application. Thus, replacing synthetic pads with natural ones like cellulose fibers will bring many positive environmental benefits as the product offers good thermal conductivity, low density, and biodegradability, owing to increasing personal care and food & beverage industries in the area. The market in the Asia Pacific region will propel the product demand over the projected period. Countries, including China, Japan, and India, have played a significant role in enhancing the nanotech profile of the region. Japan's AIST Nanocellulose Forum, for example, is focused on strengthening cooperation between industry, universities, and government.

The COVID-19 Impact:

As the COVID-19 crisis continues to intensify, producers are quickly adapting their activity and purchasing objectives to satisfy the demands of a pandemic that has limited the need for Nanocellulose in the market. A sequence of both positive and negative shocks may arise over a few months, as producers and their vendors respond to the evolving demands of customers. The export-dependent economies in several nations look weak, with an adverse global circumstance. Global Nanocellulose markets are reshaped by the effects of this pandemic, as some suppliers are either shutting down or reducing their output, due to a lack of demand from the downstream market. Although others are getting their production suspended as a precautionary step by their respective governments to prevent the spread of the virus. In certain countries, consumers based on being more regional by looking at the magnitude of the epidemic and the consequent behavior of the national authorities themselves. Under these circumstances, market conditions of the Asia Pacific regions were quite dynamic, weakening regularly, making stabilizing themselves difficult.

To identify the key trends in the industry, click on the link below:https://www.reportsanddata.com/report-detail/nanocellulose-market

Further key findings from the report suggest

Order Now: https://www.reportsanddata.com/checkout-form/3207

For the purpose of this report, Reports and Data have segmented into the global Nanocellulose market on the basis of product, distribution channel, application, and region:

Product Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Distribution Channel Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Application Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Regional Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Browse more similar reports on Materials and Chemicalscategory by Reports And Data

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John WHead of Business DevelopmentReports And Data | Web: http://www.reportsanddata.com Direct Line: +1-212-710-1370E-mail: [emailprotected] LinkedIn | Twitter | Blogs

SOURCE Reports And Data

Continue reading here:
Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data - PRNewswire

The Healthcare Nanotechnology (Nanomedicine) Market research report enhanced worldwide Coronavirus COVID19 impact analysis on the market size (Value, Production and Consumption), splits the breakdown (Data Status 2014-2020 and 6 Year Forecast From 2020 to 2026), by region, manufacturers, type and End User/application. This Healthcare Nanotechnology (Nanomedicine) market report covers the worldwide top manufacturers like (Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith&Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International) which including information such as: Capacity, Production, Price, Sales, Revenue, Shipment, Gross, Gross Profit, Import, Export, Interview Record, Business Distribution etc., these data help the consumer know about the Healthcare Nanotechnology (Nanomedicine) market competitors better. It covers Regional Segment Analysis, Type, Application, Major Manufactures, Healthcare Nanotechnology (Nanomedicine) Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Healthcare Nanotechnology (Nanomedicine)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2041239

Healthcare Nanotechnology (Nanomedicine) Market report offers comprehensive assessment of 1) Executive Summary, 2) Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Healthcare Nanotechnology (Nanomedicine) Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Healthcare Nanotechnology (Nanomedicine) Market Background, 7) Healthcare Nanotechnology (Nanomedicine) industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Healthcare Nanotechnology (Nanomedicine) Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.

Scope of Healthcare Nanotechnology (Nanomedicine) Market:It is defined as the study of controlling, manipulating and creating systems based on their atomic or molecular specifications. As stated by the US National Science and Technology Council, the essence of nanotechnology is the ability to manipulate matters at atomic, molecular and supra-molecular levels for creation of newer structures and devices. Generally, this science deals with structures sized between 1 to 100 nanometer (nm) in at least one dimension and involves in modulation and fabrication of nanomaterials and nanodevices.

Nanotechnology is becoming a crucial driving force behind innovation in medicine and healthcare, with a range of advances including nanoscale therapeutics, biosensors, implantable devices, drug delivery systems, and imaging technologies.

The classification of Healthcare Nanotechnology includes Nanomedicine, Nano Medical Devices, Nano Diagnosis and Other product. And the sales proportion of Nanomedicine in 2017 is about 86.5%, and the proportion is in increasing trend from 2013 to 2017.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Anticancer CNS Product Anti-infective Other

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Nanomedicine Nano Medical Devices Nano Diagnosis Other

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2041239

Geographically, the report includes the research on production, consumption, revenue, Healthcare Nanotechnology (Nanomedicine) market share and growth rate, and forecast (2020-2026) of the following regions:

Important Healthcare Nanotechnology (Nanomedicine) Market Data Available In This Report:

Strategic Recommendations, Forecast Growth Areasof the Healthcare Nanotechnology (Nanomedicine) Market.

Challengesfor the New Entrants,TrendsMarketDrivers.

Emerging Opportunities,Competitive Landscape,Revenue Shareof Main Manufacturers.

This Report Discusses the Healthcare Nanotechnology (Nanomedicine) MarketSummary; MarketScopeGives A BriefOutlineof theHealthcare Nanotechnology (Nanomedicine) Market.

Key Performing Regions (APAC, EMEA, Americas) Along With Their Major Countries Are Detailed In This Report.

Company Profiles, Product Analysis,Marketing Strategies, Emerging Market Segments and Comprehensive Analysis of Healthcare Nanotechnology (Nanomedicine) Market.

Healthcare Nanotechnology (Nanomedicine) Market ShareYear-Over-Year Growthof Key Players in Promising Regions.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan)production, production value, consumption, consumption value, import and exportof Healthcare Nanotechnology (Nanomedicine) market?

To Get Discount of Healthcare Nanotechnology (Nanomedicine) Market:https://www.researchmoz.us/enquiry.php?type=D&repid=2041239

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

View original post here:
Coronavirus threat to global Healthcare Nanotechnology (Nanomedicine) Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type...

KANAZAWA, Japan, June 15, 2020 /PRNewswire/ -- Researchers at Kanazawa University report in the Biophysical Journal that the process of cell removal from an epithelial layer follows from an inherent mechanical instability. Moreover, the forces generated by an extruding cell can drive the extrusion of other cells in a particular direction.

The outer or inner boundaries of organs in the human body are lined with so-called epithelial sheets. These are layers of epithelial cells that can individually change their 3D shape which is what happens during biological processes like organ development (morphogenesis), physiological equilibrium (homeostatis) or cancer formation (carcinogenesis). Of particular interest is the process of cell extrusion, where a single cell loses its 'top' or 'bottom' surface and is subsequently pushed out of the layer. A thorough understanding of this phenomenon from a mechanical point of view has been lacking, but now, Satoru Okuda and Koichi Fujimoto from Kanazawa University have discovered that there is a purely mechanical cause for cell extrusion.

Mechanically speaking, a simple (single-layer) epithelial sheet is analogous to a foam, and can be represented as a layer of interconnected polyhedra.Okuda and Fujimoto used such a foam model to describe a monolayer of epithelial cells, with each cell a polyhedron with average volume V. Every cell is further characterized by the number of neighboring cells n, the area of the apical ('top') and the area of the basal ('bottom') surface.The model, taking into account mechanical forces between neighboring cells, leads to a formula for the total mechanical energy of an epithelial sheet as a function of only a few parameters, including V and n, as well as the in-plane density and a quantity called sharpness, which can distinguish between situations where basal and/or apical surfaces are present or not. (A vanished apical surface implies basal extrusion and vice versa.) By studying how the energy changes by varying these few parameters, the researchers were able to obtain valuable insights into the mechanics of an epithelial sheet.

The key finding of Okuda and Fujimoto is that the system exhibits an inherent mechanical instability: small changes in cell topology or cell density can cause cell extrusion without additional forces being applied.Furthermore, it turns out that a cell undergoing extrusion generates forces within the layer, which can direct the extrusion of other cells to either side of the layer.

The scientists also found many agreements between the outcomes of their model and observations in living systems, such as the occurrence of different epithelial geometries (e.g. 'rosette' or pseudostratified structures).

The model admittedly has limitations, for example the assumptions that the whole sheet and the individual cell surfaces are not curved but flat. However, quoting the researchers, "despite its limitations, [the] model provides a guide to understanding the wide range of epithelial physiology that occurs in morphogenesis, homeostasis, and carcinogenesis".

BackgroundEpithelial cells

Epithelial tissue, one of four kinds of human (or animal) tissue, is located on the outer surfaces of organs and blood vessels in the human body, and on the inner surfaces of 'hollow spaces' in various internal organs. A typical example is the outer layer of the skin, called the epidermis. Epithelial tissue consists of epithelial cells; it can be just one layer of epithelial cells (simple epithelium), or two or more (layered or stratified epithelium). Satoru Okuda and Koichi Fujimoto from Kanazawa University have now modeled a simple epithelium as an arrangement of polyhedra in order to study its mechanical properties and specifically the process of epithelial cell extrusion.

Cell extrusion

In epithelial tissue, cell extrusions happen the processes whereby epithelial cells are 'pushed out' of the epithelium. Cell extrusion is an important biological process, regulating for example the removal of apoptotic (dead) cells, tissue growth and the response to cancer. Okuda and Fujimoto looked at a simple epithelium from a mechanical point of view. Modeling the epithelium as a layer of interconnected polyhedra, they found that cell extrusion whereby the top or bottom surface of a polyhedron shrinks to a point and then vanishes can be considered a purely mechanical property. An inherent instability, present in homogeneous sheets, can lead to cells being extruded due to small changes in density or topology.

Reference

Satoru Okuda, and Koichi Fujimoto. A Mechanical Instability in Planar Epithelial Monolayers Leads to Cell Extrusion, Biophysical Journal 118, 2549 (2020).

DOI: 10.1016/j.bpj.2020.03.028

URL: https://doi.org/10.1016/j.bpj.2020.03.028

About Nano Life Science Institute (WPI-NanoLSI) https://nanolsi.kanazawa-u.ac.jp/en/

Nano Life Science Institute (NanoLSI), Kanazawa University is a research center established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to form world-tier research centers. NanoLSI combines the foremost knowledge of bio-scanning probe microscopy to establish 'nano-endoscopic techniques' to directly image, analyze, and manipulate biomolecules for insights into mechanisms governing life phenomena such as diseases.

About Kanazawa University http://www.kanazawa-u.ac.jp/e/

As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.

The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

Contact :Hiroe Yoneda Vice Director of Public Affairs WPI Nano Life Science Institute (WPI-NanoLSI) Kanazawa University Kakuma-machi, Kanazawa 920-1192, Japan Email: nanolsi-office@adm.kanazawa-u.ac.jp Tel: +81-76-234-4550

SOURCE Kanazawa University

Visit link:
Kanazawa University Research: Cell Removal as the Result of a Mechanical Instability - PR Newswire UK

Industry Overview ofNano Chemotherapy Market:The research report titled, Nano Chemotherapy has adopted a systematic way to evaluate the dynamics of the overall market. It gives a definite study comprising a top to bottom research on the markets growth drivers, challenges, threats, and potential lucrative opportunities, with a key focus on global. In a chapter-wise format, the report assesses the demand and supply trends witnessed in the overall market, complete with important insights and graphical representation. An in-depth investment feasibility analysis and market attractiveness analysis is provided in the report, which makes it a miscellaneous document for players operating in the worldwide market.

Understand the influence of COVID-19 on the Nano Chemotherapy Market Size with our analysts monitoring the situation across the globe.

The novel COVID-19 pandemic has put the world on a standstill, affecting major operations, leading to an industrial catastrophe. This report presented by Garner Insights contains a thorough analysis of the pre and post pandemic market scenarios. This report covers all the recent development and changes recorded during the COVID-19 outbreak..

Access PDF Sample Copy of the Report, With 30 mins free consultation! Click here@https://garnerinsights.com/Global-Nano-Chemotherapy-Market-Size-Status-and-Forecast-2020-2026#request-sample

The research report additionally provides crucial data about the Nano Chemotherapy market overview, scope, and future viewpoint. The report additionally speaks about the market dynamics and the competitive landscape of the worldwide Nano Chemotherapy market for the mentioned forecast period of 2018 to 2026. The report is the consequence of an in-depth market research carried out with the assistance of the industry specialists. The report likewise gives data the key market players plying their trade in the global market.

The Global Nano Chemotherapy Market research report displays the market size, status, share, production, cost analysis, and market value with the forecast period 2018-2026. Other than that, upstream raw materials, downstream demand analysis, consumption volume, and the market share by segments and sub-segments have also been discussed. The research methodology of the market is based on both primary as well as secondary research data sources. It commits different factors affecting Nano Chemotherapy industry such as market environment, different policies of the government, historical data and market trends, technological advancements, forthcoming innovations, market risk factors, market restraints, and obstacles in the industry.

Major Key Players of the Nano Chemotherapy Market are:

Dell Wyse,IBM,Microsoft,Hewlett-Packard (HP),Amazon,Cisco Systems,Citrix,VMware,Rackspace,MokaFive,NComputing,

Major Types of Nano Chemotherapy covered are:

Medicine Therapy,Physical Therapy,Other,

Major Applications of Nano Chemotherapy covered are:

Hospitals,Clinics,Other,

To understand the competitive scenario of the market, an analysis of the Porters Five Forces model has also been included for the market. The research also includes a market attractiveness analysis, in which all the segments are highlighted on the basis of their market share, size, growth rate, and overall attractiveness. This market research is conducted leveraging the data sourced from the primary and secondary research team of industry professionals as well as the in-house databases. Research analysts and consultants cooperate with the key organizations of the concerned domain to verify every value of data exists in this report.

The answers to the following key questions can be found in the report:What are the key reasons to focus on this particular market?

Get Discount on this Report: https://garnerinsights.com/Global-Nano-Chemotherapy-Market-Size-Status-and-Forecast-2020-2026#discount

The report magnifies Nano Chemotherapy market competitors by exploring their newly adopted technological advancements, strategical and tactical business planning, business expansions, acquisitions, partnerships, and new product launches that gives an absolute acuity of rivalry in the Nano Chemotherapy market.The report implements various analytical tools including SWOT analysis, Porters Five Forces analysis, and Capacity Utilization analysis to render a validated evaluation of the Nano Chemotherapy market. It also comprehends futuristic business opportunities, scope as well as market threats, challenges, barriers, obstacles, and regulatory framework to give a profound idea about the Nano Chemotherapy market that aids reader to form own business stratagem accordingly to meet their resolved business goals.

Contact Us:Kevin ThomasContact No: +1 513 549 5911 (US)+44 203 318 2846 (UK)sales@garnerinsights.com

See the rest here:
Impact of Covid-19 on Nano Chemotherapy Market is Expected to Grow at an active CAGR by Forecast to 2026 | Top Players Dell Wyse, IBM, Microsoft -...

EVERGREEN, Colo., June 9, 2020 (SEND2PRESS NEWSWIRE) Combining the use of Eastern and Western philosophy of Holistic Medicine, Dr. Christina Fick, of Evergreen Medical Acupuncture, has created a carefully selected offering of CGMP (certified good manufacturing practice), and organic certified supplements and herbal products that provide a well-balanced approach to healing.

Evergreen Medical Acupuncture, a locally owned and operated Colorado Business located in Evergreen, Colorado, has always offered the best of Eastern and Western Medicine to its customers, and is happy to announce the new online store for these offering, Dr. Ficks Functional Farmacy, at https://www.drchristinafick.com/functional-farmacy.

With a wide variety of hand-picked, quality herbal supplements with a focus on some of the best practices of Eastern Medicine, Dr. Ficks Functional Farmacy provides clients the ease of online information and recommendations, and the ability to order products from home. Products such as Phyto-Multiplex, a multi-vitamin + phytonutrient + trace mineral supplement, Premium Choline for brain, gut, and general health, and Nutra-Absorb for digestive support, are now ready for the online audience.

Dr. Ficks Functional Farmacy is also offering an exclusive cosmetic line, Skin for Life, and a selection of specialty luxury soaps, called My Soap Box. Skin for Lifes ingredient formulas are in a nutritional nano bio-emulsion sphere that delivers vitamins, minerals, and essential lipids to protect the skins immunity integrity, and the beautifully scented, exotic body and facial bar soaps of My Soap Box are a perfect way to provide an escape from the days stresses, or to provide a truly unique gift for someone dear to you.

We offer the best of Eastern and Western Medicine to our clients The Chinese now see the benefit of modern medicine, and how it can be applied to the practice of Traditional Chinese Medicine, stated Dr. Christina Fick. By combining the best of both worlds, we can achieve sustainable results for our clients using Acupuncture, Specialty Needle Techniques, and our custom-built Acupuncture Clinic. These herbal supplements and new products represent some of our best recommendations, and compliment these techniques, and are now available to clients with a mouse-click.

About Evergreen Medical Acupuncture, Dr. Ficks Functional Farmacy, and Dr. Christina Fick

Located in both Evergreen, Colorado, Evergreen Medical Acupuncture is locally owned and operated. The company and its employees live and work in Colorado, and also offer phone or video chat appointments for consultation to anyone in the nation. The acupuncturists on in the Clinic work closely under Dr. Fick, have been hand-selected and vetted, and go through rigorous ongoing training to provide highest standards of service and customer care.

Dr. Christina Fick is the owner and founder of Evergreen Medical Acupuncture, LLC, first opened in 2012. She holds a Doctorate in Acupuncture and Oriental Medicine, a Masters degree in Herbology, and is certified in Functional Medicine. She has worked globally in her specialized field, in hospitals both in China, and in New York.

For more information about Dr. Ficks Functional Farmacy, and Evergreen Medical Acupuncture, including details about their services and new custom built Acupuncture Clinic, please visit the company website: https://www.drchristinafick.com/, or call to book an appointment or learn more at 303-594-8348.

*PHOTO link for media: https://www.Send2Press.com/300dpi/20-0609s2p-evergreen-med-300dpi.jpg

Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

News Source: Evergreen Medical Chiropractic and Acupuncture

To view the original post, visit: https://www.send2press.com/wire/evergreen-medical-acupuncture-is-now-offering-its-own-supplement-and-herbal-products-dr-ficks-functional-farmacy/.

This press release was issued by Send2Press Newswire on behalf of the news source, who is solely responsible for its accuracy. http://www.send2press.com.

See original here:
Evergreen Medical Acupuncture is now offering its own supplement and herbal products, Dr. Ficks Functional Farmacy! - TippNews DAILY

Many of us have traumatic memories of going to the doctor to get the flu shot or childhood vaccines when we were younger. This feeling isnt uncommon as 17 per cent of the population suers from anxiety or needle phobia. Your child self wasnt being irrational eitherneedles have proven to be a pain for the medical industry as well.

Although the transdermal patch has gained popularity over the years as an innovative way to deliver medicine into ones system, jet injectors have also made waves due to their benefits in rapid administration, improved dosing accuracy, faster response rates, better diffusion into tissues, and reduced sharps waste, according to a report by Grand View Research.

For those who dread needles, a solution is on the way, and its becoming a much more pervasive method of delivering drugs, without the associated fear. As needles become outdated, Inolife R&D is working on a method to implement needle-free injections with its pipeline of prototypes for the next generation of technology.

The point of needle-free

Inolife is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies. The company commercializes FDA-cleared and CE approved needle-free injection systems catering to a wide range of applications. Being CE approved is particularly impressive as it means that they are conform to all health, safety and environmental concerns in Europe, which are among the strictest in the world. They have also long been focused on research and development, having acquired Dutch company, European Pharmagroup, to tap into their existing global knowledge base.

Michael Wright, CEO and President, Inolife R&D.

The need for needle-free injectors goes far beyond visits to the doctor for vaccines, and the potential market benefit is massive. Some of these applications include potential use for diabetes, dental anesthesia, vaccinations, autoimmune disease, erectile dysfunction, cancer treatments, growth hormones, cosmetics (for injections of Hyaluronic Acid and similar products), and veterinary applications.

Diabetes is especially one of the fastest-growing diseases around the globeit is estimated that 374 millionpeople are at increased risk of developing type 2 diabetes.Dr. Ricordi, M.D., and Inolifes Advisory Board member, works closely with the company on improving solutions for diabetics.

He explains his involvement, "It is my professional life mission to help people who have diabetes. Inolife's synergistic mission makes us excellent strategic partners. Their technology allows diabetes patients to inject their medication without needles, with the objective of increasing care plan compliance and improving overall outcomes.

I look forward to working with Inolife to positively impact the world through novel drug delivery system development.

Inolife is bringing to market injectors that can allow for at-home insulin injections, entirely without the usage of a needle. As Michael Wright, CEO and President of Inolife notes, Cross-contamination when handling needles is a major concern globally.

Our devices have no needles and do not perforate the skin while injecting and therefore, the risk of a needlestick injury is eliminated and when done, it does not require the same costly process for disposal as a biohazard. It can be discarded or eventually recycled.

Moreover, needles are dangerous and complicated to dispose of, providing a serious biohazard after use. Many viruses can live up to 48 hours on a needle, and special biohazard bins are needed for disposal. With no needle, these concerns vanish.

Not just in science fiction

So how exactly do you inject without a needle? While each product in the Inolife family is slightly different, they all work on the same principle. Regular needles work by puncturing the skin to deliver a pool of liquid into the tissue, but the Inolife needle-free injectors deliver the fluid just under the epidermis in the subcutaneous layer by a fine high-speed jet stream.

Because there is no needle penetrating the skin, theres a smaller chance of infection. Its also much more efficient, as the medicine spreads out evenly, rather than creating a pooling effectso in the case of being used for anesthetics, you wont get that uncomfortable situation where a dentist has to inject you multiple times in multiple places. It also has a much faster uptake. The dermal layer is what protects our body, and our body thus reacts fastest to materials spread into the first line of defense.

Inolife also carries Ino 100 which is a self-injectable that can be used for up to 50 injections per nozzle. It harbours the following characteristics as well:

The COVID-19 pandemic truly proves the importance that remote medicine is going to have in the future.

Partnerships for success

Interest in Inolife has already led to a series of partnerships, joint ventures and endorsements, as the company is searching to make a difference on a global scale. It was joint ventures with pharmaceutical companies that helped develop the key nano-powder described above. These partnerships will allow for a global supply chain to patients across the globe when larger-scale production begins.

Many of those interested in Inolife are major players in global health. For example, Pharmajet, works closely with the World Health Organization (WHO) in adapting needle-free injectors for use in vaccines. The pharmaceutical industry in general has expressed a keen interest in the technology, as it anticipates a future demand for more user-friendly devices and whats more user friendly than dropping needles?

Governments have also taken note. Israel expressed its approval of the technology, and former Mexican President and Legal Representative of Centro Fox, Vincente Fox, was so interested that he became an advisor of the company.

The full press release can be viewed here.

He explains, To Centro Fox and myself, personally, this represents a great opportunity to accomplish our plan of removing the risk of needle stick injuries and cross contamination for care givers, as well as reduce anxiety for patients. Our main driver is to think of patient comfort at the system-level as well as improve home care compliancy. We want to fundamentally change how physicians and patients interact.

He adds, Now that Inolife Sciences has shown a viable and proven business model, we are moving to partner with pharmaceutical companies to enhance their therapeutic applications and compliancy by using Inolifes current technologies. We also look into the very near future and see the positive impact the Inolife nanoparticle powder injection technology could have on the entire injection marketwe can expect a few more partnerships this year and, in the years, to come.

Inolife is also looking to partnerships to perhaps expand beyond the medicines it already envisions. Studies in collaboration with McGill University are looking to develop a cannabidiol injectable to compete with other drugs for chronic pain and inflammation.

Plans for the Future

Wright is organizing private fundraising and is getting ready to take the company into public listing, which is a crucial milestone that investors should keep an eye peeled for. While a lot of focus has been on R&D and partnerships, Wright has expressed his interest in a scalable business, selling not just the injectors but the supply of the disposable syringes and further developed nano-powder injectables.

Clinical testing is also running at full steam on many of their planned products. Inolife was founded with the intention to positively impact peoples wellbeing and it is only warming up to the task. The invention of the hypodermic needle was once a medical breakthrough. One day, however, it may end up in a museum as an outdated relic, only serving as a story to scare our children about how we used to take our medicine.

Learn more about Inolife by visiting their website here.

See how the companys technology works by watching their YouTube video below.

For more investor-related information please email Chris Brown, Global Capital Markets or Michael Wright, CEO, Inolife Sciences.

Read more from the original source:
Inolife is going to revolutionize how we take our medicine - BNNBloomberg.ca

Ming-Chen Sun,1,* Xiao-Ling Xu,1,* Xue-Fang Lou,2 Yong-Zhong Du1

1Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Peoples Republic of China; 2School of Medicine, Zhejiang University City College, Hangzhou 310015, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Yong-Zhong DuInstitute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yu-Hang-Tang Road, Hangzhou 310058, Peoples Republic of ChinaTel +86-571-88208435Fax +86-571-88208439Email duyongzhong@zju.edu.cnXue-Fang LouSchool of Medicine, Zhejiang University City College, 51 Hu-Zhou Street, Hangzhou 310015, Peoples Republic of ChinaTel +86-571-88013011Fax +86-571-88018442Email louxf@zucc.edu.cn

Abstract: Vitiligo is a depigmentation disease that seriously affects the physical health, mental health and quality of life of a patient. Therapeutic aim at control immunoreaction by relieving oxidative stress. Unfortunately, the cuticle barrier function and lack of specific accumulation lead to unsatisfactory therapeutic outcomes and side effects. The introduction and innovation of nanotechnology offers inspiration and clues for the development of new strategies to treat vitiligo. However, not many studies have been done to interrogate how nanotechnology can be used for vitiligo treatment. In this review, we summarize and analyze recent studies involving nano-drug delivery systems for the treatment of vitiligo, with a special emphasis on liposomes, niosomes, nanohydrogel and nanoparticles. These studies made significant progress by either increasing drug loading efficiency or enhancing penetration. Based on these studies, there are three proposed principles for topical nano-drug delivery systems treatment of vitiligo including the promotion of transdermal penetration, enhancement of drug retention and facilitation of melanin regeneration. The presentation of these ideas may provide inspirations for the future development of topical drug delivery systems that will conquer vitiligo.

Keywords: vitiligo, nano-drug delivery system, transdermal penetration, liposomes, skin

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
Recent Progress and Future Directions: The Nano-Drug Delivery System f | IJN - Dove Medical Press